2-羟基-5-甲基-3-硝基苯乙酮 、 4-苄氧基苯甲醛 以to give 150 mg (Yield 75%) of the title compound的产率得到(E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-5-methyl-3-nitrophenyl)-2-propen-1-one
参考文献:
名称:
Cdk inhibitors having 3-hydroxychromen-4-one structure
Cdk inhibitors having 3-hydroxychromen-4-one structure
申请人:——
公开号:US20030125356A1
公开(公告)日:2003-07-03
The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.
CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE
申请人:LG Life Sciences Ltd.
公开号:EP1280789A1
公开(公告)日:2003-02-05
US6683095B2
申请人:——
公开号:US6683095B2
公开(公告)日:2004-01-27
[EN] CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE<br/>[FR] INHIBITEURS DE CDK AVEC STRUCTURE 3-HYDROXYCHROMEN-4-UNE
申请人:LG CHEM INVESTMENT LTD
公开号:WO2001083469A1
公开(公告)日:2001-11-08
The present invention relates to a novel 3-hydroxychromen-4-one derivative of formula (1), pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase ('CDK'); to a process for preparing the compound of formula (1); and to a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. comprising the compound of formula (1) as an active component together with pharmaceutically acceptable carriers.
CDK inhibitors having 3-hydroxychromen-4-one structure
申请人:LG Life Sciences Ltd.
公开号:US06683095B2
公开(公告)日:2004-01-27
A novel 3-hydroxychromen-4-one derivative, pharmaceutically acceptable salt, hydrate, solvate or isomer thereof which is useful as an inhibitor for Cyclin Dependent Kinase (“CDK”) is disclosed. Further, a process for preparing the compound and a composition for suppression or treatment of cancer and diseases induced by cell proliferation such as inflammation, angiostenosis, angiogenesis, etc. is disclosed comprising the compound as an active component together with pharmaceutically acceptable carriers.